Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04806035 · ClinicalTrials.gov registry record · Phase 1
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04806035 is a Phase 1 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT04806035, a Phase 1 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.
Interventions
- BIOLOGICAL Ublituximab
- BIOLOGICAL TG-1801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04806035
The ClinicalTrials.gov registry entry for NCT04806035 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ublituximab is the first listed.
NCT04806035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04806035 about?
NCT04806035 is a clinical study titled "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia". The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.
What is the current status of trial NCT04806035?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-04-28. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT04806035?
The interventions under investigation include: Ublituximab (BIOLOGICAL), TG-1801 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04806035?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.